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ABSTRACT 
 
Endothelial cells lining the vessel wall are connected by adherens, tight and gap 
junctions. These junctional complexes are related to those found at epithelial junctions but 
with notable changes in terms of specific molecules and organization. Endothelial junctional 
proteins play important roles in tissue integrity but also in vascular permeability, leukocyte 
extravasation and angiogenesis. In this review, we will focus on specific mechanisms of 
endothelial tight and adherens junctions. 
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INTRODUCTION 
The endothelium is located at the inner side of all vessel types and is constituted by a 
monolayer of endothelial cells. Interendothelial junctions contain complex junctional 
structures, namely adherens junctions (AJ), tight junctions (TJ) and gap junctions (GJ), 
playing pivotal roles in tissue integrity, barrier function and cell-cell communication, 
respectively. The endothelium constitutes the vascular barrier with regulated permeability 
properties between the blood and the underlying tissues. Quiescent endothelium may be 
subjected to stimuli inducing leukocyte extravasation at inflammatory sites and sprouting 
angiogenesis. Both processes have a strong impact on endothelial cell-cell junctions. In this 
review, we will focus on endothelial AJ and TJ as well as interendothelial-specific molecules 
or mechanisms in resting and activated vessels. 
 
Histology of endothelial junctions 
The junctional structures located at the endothelial intercellular cleft are related to those 
found in epithelia; however, their organization is more variable and in most vascular beds 
their topology is less restricted than in epithelial cells. AJ, TJ and GJ are often intermingled 
and form a complex zonular system with variations in depth and thickness of the 
submembrane plaque associated with the junctional structure [1, 2]. As opposed to epithelial 
cells, GJs are often observed close to the luminal surface. Therefore, the term “apical 
junction” used to collectively designate epithelial TJ and AJ may not be applied to the 
endothelium. 
Another distinction comes from the difference in cell thickness. With some exceptions, 
cell body thickness of microvascular endothelium is less than 0.3 m [2]. Overlapping strands 
of adjacent endothelial cells form contact domains of 0.5-0.9 m. However, endothelial cell-
cell contacts of some other vessels, including arteries and high endothelial venules, may reach 
3-10 m (Fig. 1) (deduced from [1, 2]). Outside of the electron-dense junctional structures, 
the intercellular cleft is lined by parallel plasma membranes of neighbor cells separated by 10-
20 nm.  
Finally, endothelial intercellular domains differ from those of epithelial cells by the 
absence of desmosomes [2]. The intermediate filaments, constituted in the endothelium by 
vimentin molecules, are poorly linked to cell-cell contacts. However, as opposed to the 
situation in epithelia, the vimentin filaments may be linked to endothelial AJ in junctional 
structures similar to desmosomes, called complexus adherens [3-8]. These structures 
originally described in lymphatic endothelium may have a broader distribution in the vascular 
tree. 
It must be stressed that interendothelial junctions are dynamic structures, subjected to 
multiple regulations. Furthermore, leukocytes extravasate at inflammatory sites (mostly in 
postcapillary venules) either through transcellular or paracellular routes. Extravasation 
through the intercellular junction is a rapid and regulated process, during which the leukocyte 
is squeezed in the cleft (diapedesis), followed by rapid junction reformation. 
 
Adhesive proteins located at endothelial cell-cell contacts 
A number of proteins exhibiting homophilic adhesive activities are located at 
interendothelial contacts (Fig. 2). Some of them are specific to endothelial cells (e.g., VE-
cadherin [9, 10], claudin-5 [11]) while others are common with epithelial cells (e.g., occludin 
[12], junctional adhesion molecule (JAM)-A [13], nectins [14, 15], claudins (see references 
below) and connexins [16]), blood cells (e.g., PECAM/CD31 [17], endothelial cell-selective 
adhesion molecule (ESAM) [18, 19], JAM-A, -C, CD99 (reviewed in [20]), smooth muscle 
cells (S-endo-1/CD146 [21]) or mesangial/trophoblast cells (protocadherin (Pcdh)12/VE-
cadherin-2 [22]). These proteins may be part of organized junctional structures, such as VE-
4 
cadherin in AJ, claudins and occludin in TJ, or connexins in GJ, while others are independent, 
such as PECAM, CD99, S-endo-1 or Pcdh12. The JAMs are associated with TJ through 
intracellular components without being directly involved in TJ strand formation.  
Interendothelial adhesive proteins are implicated at different levels in endothelial cell-cell 
interaction and tissue integrity. Some of them have a dual function as they also participate in 
leukocyte extravasation via homophilic (PECAM, CD99, JAM-A, -C) or heterophilic (JAM-
A, -B, -C) interactions (reviewed in [20]).  
 
THE ENDOTHELIAL ADHERENS JUNCTION 
 
The VE-cadherin-based complex and its physiological role 
VE-cadherin is the transmembrane component of endothelial AJ [23]. It is a type II 
cadherin harboring high adhesive activity [24]. Several biochemical evidences showed that 
VE-cadherin extracellular domains form hexamers in solution [25, 26]. Electron microscopy 
data support this view and allowed to propose a model in which VE-cadherin dimers interact 
in trans through their extracellular domain 1 and VE-cadherin trimers interact in cis via their 
extracellular domain 4 (Fig. 3) [27].  
VE-cadherin intracellular domain is similar to other classical cadherins. It contains a 
proximal binding site for p120 and p0071, and a distal binding site for ß-catenin and 
plakoglobin (Fig. 4, left). Both ß-catenin and plakoglobin are linked to -catenin, which may 
further interact with -actinin and vinculin (see [28] and references therein). The identity of 
the molecular link for the actin filament anchorage to the cadherin-catenin complex is still a 
question of debate [29]. As previously indicated, the VE-cadherin complex may associate 
with the vimentin cytoskeleton in some vascular locations [3-8]. This association is mediated 
by either plakoglobin or p0071, both interacting with desmoplakin, which in turn associates 
with vimentin (Fig. 4, right). The VE-cadherin complex also transiently or permanently 
associates with signaling partners (see below), and with a specific apical-basal polarity 
complex, through direct interaction with PAR-3 and PAR-6 [30].  
The precise mechanisms of VE-cadherin-based junction formation remain mostly 
unexplored. However, Delanoë-Ayari et al. [31] proposed a model in which VE-cadherin 
lateral clustering may be achieved by membrane tension and free VE-cadherin molecule 
diffusion rather than a cytoskeleton-driven mechanism. Consistent with this hypothesis, VE-
cadherin clusters forming artificial AJ were observed by assembly of VE-cadherin 
extracellular domains at the surface of liposomes [32]. As described below, the first cell-cell 
contacts may be achieved by nectin interaction, which may facilitate cadherin binding. 
VE-cadherin was shown to be specifically located at junctions of all endothelium 
subtypes [9]. VE-cadherin mRNA were observed at the onset of vasculogenesis in the mouse 
embryo [10]. Its extraendothelial expression has been observed in case of vascular mimicry 
(the extravillous cytotrophoblasts replacing the spiral artery endothelium [33] or melanoma 
cells lining tumor vessels [34]), in circulating endothelial progenitors [35] and in podocytes 
[36].  
The VE-cadherin gene yields a single transcript and its promoter contains functional sites 
for transcription factors such as Ets and Sp1 family members, as well as Tal [37-40]. 
Although constitutively expressed by endothelial cells, VE-cadherin expression is enhanced 
by basic FGF in angiogenic situations [41]. Furthermore, Tal, a bHLH transcription factor 
dramatically upregulated during angiogenesis, activates VE-cadherin transcription [40].  
VE-cadherin adhesive properties are essential for optimal homotypic cell interaction; 
however, the observation that VE-cadherin-deficient embryos retained electron-dense 
endothelial junctions indicates that some redundancy exist between the several homophilic 
adhesive proteins located at the endothelial surface [42]. Furthermore, VE-cadherin-deficient 
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embryos exhibited defective capacities in sprouting angiogenesis resulting in embryonic death 
at midgestation, suggesting that VE-cadherin has signaling properties required for vascular 
morphogenesis. The dramatic phenotype of VE-cadherin-deficient embryos was similar to 
that obtained with partial truncation of VE-cadherin cytoplasmic domain [43]. This feature 
further points to the implication of VE-cadherin in intracellular signaling.  
The contribution of VE-cadherin in neovessel formation has been further demonstrated in 
adults by experiments using antibodies directed against specific VE-cadherin epitopes, 
unmasked during angiogenesis, that abrogated angiogenesis and tumor growth in mice [44-
46].  
Other cadherins, namely N-cadherin [47], T-cadherin [48] and Pcdh12 [22, 49], have also 
been located in endothelial cells. Albeit abundant in endothelium, N-cadherin is not or poorly 
located at interendothelial junction [47]. Several converging studies indicate that this 
molecule promotes heterotypic interactions with perivascular cells such as pericytes [50, 51]. 
T-cadherin has been identified in endothelium of human aorta [48]. In vitro studies indicate 
that T-cadherin may participate to various cellular processes, including migration, 
proliferation and survival [52-55]. Pcdh12 is located at interendothelial junctions, mostly in 
angiogenic endothelium, and its function is presently unknown [22, 49]. 
 
-catenin trafficking in endothelial cells 
As described for epithelial cells, ß-catenin may translocate to the nucleus and activate 
several genes including cyclin D1 and myc whose products induce entry in the cell cycle [56]. 
During human embryonic development, ß-catenin was detected in endothelial cell nuclei 
and cytoplasms of capillaries (in particular in the brain), arteries and veins [57-59]. In 
quiescent endothelial cells of adults, ß-catenin is detectable neither in the nucleus nor in the 
cytoplasm, but appears to be concentrated at cell-cell contacts. Conversely, ß-catenin is often 
observed in the nucleus and cytoplasm of endothelial cells during pathological angiogenesis 
or vascular remodeling. Consistently, intracellular (nuclear or cytosolic, as opposed to 
junctional) accumulation of ß-catenin correlates with BrDU incorporation, which therefore 
links the presence of intracellular ß-catenin to a proliferative state. 
The conditional inactivation of ß-catenin in the endothelium leads to morphological 
alterations of vessels, increased vascular permeability and eventually results in embryonic 
lethality at mid-gestation [60, 61]. In endothelial cells devoid of ß-catenin, plakoglobin solely 
binds to VE-cadherin. As opposed to ß-catenin, plakoglobin may bind to either -catenin or 
desmoplakin and vimentin. Therefore, the VE-cadherin complex may interact more strongly 
with the vimentin cytoskeleton in this context. 
Altogether, these features suggest that physiological regulation of endothelial junctions 
depends on (i) a subtle balance between ß-catenin and plakoglobin binding to VE-cadherin 
and (ii) the proportion between intracellular and junctional ß-catenin. 
 
Regulation of VE-cadherin barrier function 
Beside its role in maintaining endothelium integrity, VE-cadherin participates in the 
control of vascular permeability and leukocyte transmigration, as documented by injection of 
VE-cadherin function blocking antibodies in the mouse [62-64]. During leukocyte 
transmigration, VE-cadherin-catenin complexes are pushed aside to facilitate diapedesis [65-
67]. An alternative mechanism has been described that implicates the degradation of VE-
cadherin molecules by various proteases, as discussed below. 
VEGF (vascular endothelial growth factor) is a pleiotropic cytokine relatively specific to 
endothelial cells or their progenitors inducing vascular permeability, cell survival or 
proliferation in a context-dependent manner [68]. In confluent endothelial cells, VEGF 
induces a rapid and transient tyrosine phosphorylation of VE-cadherin as well as ß-catenin 
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and plakoglobin [69]. These molecular events are accompanied by increased paracellular 
permeability and decreased association of the VE-cadherin complex with the cytoskeleton. 
Furthermore, VEGFR2, the receptor transducing VEGF signals in endothelial cells, interacts 
with the VE-cadherin complex, probably through ß-catenin [43, 70]. VE-cadherin tyrosine 
phosphorylation and association to VEGFR2 was confirmed in vivo in a model of 
physiological angiogenesis dependent on VEGF [71]. Src tyrosine kinase is constantly 
associated with VE-cadherin [71]. Chou et al. [72] showed that Src also associates with 
VEGFR2 and gets activated upon VEGF stimulation. Src inhibitors prevent VEGF-induced 
VE-cadherin phosphorylation, thereby indicating that Src is an obligatory mediator in this 
pathway [71]. Furthermore, Src directly phosphorylates VE-cadherin cytoplasmic domain on 
tyrosine 685 (Fig. 5A) [73]. The functional consequences of Y685 phosphorylation remain 
elusive, although a direct binding of C-terminal Src kinase (Csk) to phospho-Y685 has been 
reported (see below) [74]. Other VE-cadherin tyrosine phosphorylation sites (Y658 and 
Y731) have been described in correlation with increased permeability [75]. 
Recently, Gavard et al. [76] revealed an additional role of VEGF in VE-cadherin 
endocytosis and thus junction opening (Fig. 5B). VEGF induces the activation of the 
exchange factor Vav2 via Src. Vav2 activates Rac, which in turn activates PAK kinase, 
enabling phosphorylation of VE-cadherin cytoplasmic domain on serine 665. Phospho-S665 
VE-cadherin becomes a docking site for ß-arrestin-2, the binding of which triggers VE-
cadherin endocytosis. 
VEGF is not the sole endothelial effector inducing tyrosine phosphorylation of the VE-
cadherin complex. Other permeability factors, including histamine, tumor necrosis factor 
(TNF)-, platelet-activating factor (PAF) as well as activated neutrophils or integrin 
engagement phosphorylate VE-cadherin [77-83]. 
In quiescent vessels, VE-cadherin is in a dephosphorylated state. Several protein tyrosine 
phosphatases are associated with VE-cadherin: Dep-1 [84], VE-PTP [85], PTP- [86, 87] and 
SHP-2 [88]. VE-PTP and PTP-, two integral membrane proteins, directly interact with VE-
cadherin extracellular and intracellular domains, respectively. Both phosphatases were shown 
to dephosphorylate VE-cadherin after VEGF stimulation, leading to increased barrier 
function.  
VE-cadherin extracellular domain is highly sensitive to proteolysis and a 90 kDa-related 
protein corresponding to its extracellular domain is often detected in tissue extracts [71]. 
Whereas VE-cadherin cleavage by activated neutrophils has been a question of debate, 
some evidences indicate that proteases liberated by or at the surface of stimulated neutrophils 
[89], namely neutrophil elastase and cathepsin G [90] and probably others [91], cleave VE-
cadherin, thereby facilitating neutrophil transmigration.  
VE-cadherin degradation by matrix metalloproteinase, such as MMP-2, -7 and -9, has 
been documented in several settings, including apoptosis, diabetes and Dengue virus infection 
[92-96].  
VE-cadherin is also degraded by clathrin-dependent endocytosis and lysosomal targeting 
by a mechanism involving p120 [97-100]. P120 downregulation in endothelial cells induces a 
dramatic decrease in barrier function associated with a loss of VE-cadherin protein levels. 
P120 may thus be an intracellular regulator of VE-cadherin degradation. 
In conclusion, several pathways co-exist to reduce VE-cadherin-dependent barrier 
function: VE-cadherin/catenins complex dissociation from the cytoskeleton, VE-cadherin 
internalization, junctional movements and VE-cadherin degradation. 
 
Contact inhibition of cell proliferation as a consequence of junction formation 
The essential role of VE-cadherin in contact inhibition was revealed by two in vitro 
experiments. In a first study, Dejana’s group showed that proliferation was inhibited when 
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endothelial cells were seeded on dishes onto which the extracellular VE-cadherin domain had 
been adsorbed [101]. More recently, the same group reported that VE-cadherin-deficient 
endothelial cells had lost their contact inhibition and reached increased cell density [84].  
Several signaling pathways were identified that may explain the growth inhibition 
controlled by VE-cadherin. 
(1) VE-cadherin might sequester ß-catenin at the membrane, thereby preventing 
transcriptional activation of proliferative genes. Interestingly, a study exploited this property 
by ectopically expressing the VE-cadherin cytoplasmic domain in tumor cells, to successfully 
block ß-catenin transcriptional activity and specifically kill these cells [102]. 
(2) VE-cadherin binding to VEGFR2 leads to a dramatic decrease in VEGFR2 tyrosine 
phosphorylation [84]. Consequently, both MAP kinase activation and cellular proliferation are 
reduced. The protein tyrosine phosphatase Dep1, associated to the VE-cadherin complex, 
might be responsible for VEGFR2 dephosphorylation (Fig. 6). More recently, the mechanism 
by which VE-cadherin attenuates VEGF proliferative signal has been further deciphered 
[103]. Junctional VE-cadherin reduces VEGFR2 internalization after VEGF activation and 
decreases receptor signaling from endosomal compartments by a Dep1-dependent 
mechanism. Conversely, in sparse cells, VEGFR2 is internalized faster and its proliferative 
activity lasts longer.  
(3) VE-cadherin interacts with Shc, a protein known to activate the MAP kinase cascade, 
after stimulation with VEGF [104]. This binding leads to Shc dephosphorylation probably by 
junctional VE-cadherin-associated phosphatases. Phospho-Shc is able to couple Grb2-Sos to 
Ras, which eventually activates the MAP kinases (Fig. 6) [105]. Therefore, junctional docking 
of Shc and its subsequent dephosphorylation may inhibit VEGF proliferative activity. 
(4) The protein tyrosine kinase Csk (C-terminal Src kinase) is a negative regulator of the 
Src family kinases that inactivates these enzymes by phosphorylation of their inhibitory 
tyrosine, thereby imposing a locked conformation [106]. Analysis of chimeric embryos 
containing Csk-deficient and wild type cells revealed defects in angiogenic sprouting and 
vascular remodeling, a phenotype reminiscent of VE-cadherin-deficient embryos [107]. Csk 
binds to VE-cadherin cytoplasmic domain when Y685 is phosphorylated (Fig. 5A) [74] and 
Csk siRNA inhibition in endothelial cells increases proliferation. It is thus likely that VE-
cadherin participates in cell contact inhibition by recruitment of Csk and inhibition of Src 
activity. 
(5) Finally, by culturing endothelial cells on patterned substrates, Nelson and Chen [108] 
showed that VE-cadherin may inhibit proliferation by actively decreasing cell spreading. By 
preventing the VE-cadherin-induced change in morphology, the authors revealed that VE-
cadherin also elicit a growth signal mediated by actin cytoskeleton tension. 
 
VE-cadherin implication in VEGF survival signaling and the endothelial hemodynamic 
force response 
Quiescent endothelial cells are resistant to harmful stimuli, such as serum deprivation. 
Similar to other cadherin members, VE-cadherin protects endothelial cells from serum 
deprivation-induced apoptosis. Yet, VEGF-induced phosphorylation of PI3 kinase and 
subsequent activation of the serine-threonine kinase Akt is enhanced by VE-cadherin and its 
binding to the VEGFR2 complex (Fig. 6) [43].  
In addition, VE-cadherin induces Gas1 (growth arrest-specific 1) expression [109]. This 
protein efficiently protects cells from apoptosis. Interestingly, VE-cadherin-blocking 
antibodies prevent VEGF-induced stimulation of Gas1 expression, suggesting that junctional 
assembly of VE-cadherin is required for Gas1 induction. 
Therefore, VE-cadherin acts both as a junctional sensor and a molecular switch, directing 
VEGF signaling towards proliferation or survival. 
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Endothelial cells are also exposed to and activated by the bloodstream. Hemodynamic 
forces are variable along the vascular tree and induce a complex response in the endothelium, 
including the induction or repression of several genes as well as modifications in cell 
morphology. Junction resistance to flow stress is dependent upon VE-cadherin, and more 
specifically upon its binding to plakoglobin [110]. Furthermore, loss of VE-cadherin 
precludes transcriptional activation of a shear stress-responsive promoter. In fact, VEGFR2, 
VE-cadherin together with PECAM/CD31 form a mecanosensor complex that is sufficient to 
activate a flow-response to heterologous cells [111, 112].  
 
VE-cadherin and cytoskeleton organization through G protein activation 
Cadherins are good candidates as mediator of cytoskeletal organization modifications, 
such as those observed during epithelio-mesenchymal transition. An increasing number of 
studies indicates that cadherin engagement induces activation of Rho family GTPases.  
Rac activity is associated with endothelial junction strengthening. Yet, its inhibition 
induces endothelial junction disruption [113]. Rac may act by promoting actin polymerization 
or by coupling the VE-cadherin complex to the cytoskeleton [114].  
A recent study shows that acute hypoxia transiently inhibits Rac1, leading to RhoA 
activation, actin stress fiber formation, adherens junction opening and eventually increased 
endothelial permeability. Conversely, re-oxygenation strongly activates Rac1 and restores the 
cortical location of actin filament by inhibiting RhoA [115].  
The endothelium is separated from interstitial collagens by a basal lamina constituted by 
several proteins, including laminins. Laminin I induces a sustained activation of Rac, 
correlated with endothelial quiescence, while collagen I, to which sprouting cells are exposed, 
triggers adherens junction disruption and capillary morphogenesis associated with and 
dependent of Rho activation [116]. 
Intriguingly, a recent study reports the activation of Rac1 in VEGF-treated endothelial 
cells, which transiently prevents VEGF-induced paracellular permeability [117]. A dominant-
negative form of Rac1 abolishes the transient barrier effect, whereas the established and 
sustained effect of VEGF is unmodified. 
Numerous reports indicate that Rac activity increases the endothelial barrier. However, 
this notion was challenged by van Wetering et al. [118], who showed that expression of 
constitutively active Rac in endothelial cells caused a rapid and ROS (reactive oxygen 
species)-dependent disruption of cell junctions. The same group further demonstrated that 
activation of Rac and subsequent production of ROS resulted in ß-catenin phosphorylation by 
the tyrosine kinase Pyk2 [119]. As mentioned above, Rac also participates in VE-cadherin 
internalization after VEGF stimulation [76]. 
Altogether, these results show that Rac is involved in several signaling pathways leading 
to either endothelial barrier reinforcement or increased permeability. 
Whether it is clearly demonstrated that Rho and Rac are potent effectors of VE-cadherin 
adhesive activity, the reverse is also true. Hence, VE-cadherin re-expression in VE-cadherin-
deficient endothelial cells increases Rac activity by augmenting the expression of Rac-
specific guanosine-exchange factor Tiam1 [120]. Furthermore, VE-cadherin re-expression 
increases the membrane-associated pools of Tiam1, Rac and its effector PAK (p-21 activated 
kinase). These properties are lost when VE-cadherin lacks domains interacting with p120 or 
ß-catenin.  
VE-cadherin also regulates RhoA, which in turn transmits signals via the actin 
cytoskeleton to adhesive proteins implicated in cell-matrix attachment [108, 121]. As 
previously mentioned, following cell-cell contacts, this signaling may limit endothelial cell 
spreading. 
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Hence, VE-cadherin, by interfering with small G-protein activity, may act on 
cytoskeleton organization, cell spreading and matrix adhesion. 
The GTPase Cdc42 also controls VE-cadherin activity. Indeed, a dominant-negative 
mutant of Cdc42 dramatically decreases endothelial junction reformation, following an 
inflammatory stimulation like thrombin [122]. The same group further demonstrated that 
Cdc42 acts on adherens junctions by controlling the binding of -catenin to the ß-catenin/VE-
cadherin complex [123]. Remarkably, the cytoplasmic domain of extrajunctional VE-cadherin 
is capable to induce formation of extended membrane protrusions by a Cdc42-dependent 
mechanism [124]. Hence, Cdc42 controls VE-cadherin protrusive activity by an inside-out 
signaling pathway utilizing actin polymerization. This mechanism, together with the potent 
heterophilic adhesion of VE-cadherin with fibrin [125], may play a pivotal role in capillary 
morphogenesis.  
Cyclic AMP (cAMP) is a second messenger acting downstream of G-protein-coupled 
receptors, whose production increases endothelial barrier function [126]. Receptor agonists, 
such as prostacyclins or prostaglandins, attenuate the hyperpermeability induced by 
inflammatory stimuli [127]. A recent study shed light on the role of Rap1, a Ras family 
GTPase, in this process [128]. Elevated levels of intracellular cAMP enable the activation of 
the exchange factor Epac, which is a specific activator of Rap1. Epac or Rap1 activation 
decreases permeability by promoting the extension of VE-cadherin-based junctions (Fig. 7) 
[129]. Another report indicates that the homophilic engagement of VE-cadherin is sufficient 
to activate Rap1, by a mechanism dependent on the adaptor protein MAGI-I [130]. This 
protein, probably recruited at the junction by ß-catenin, is associated with the exchange factor 
PDZ-GEF1, which is a direct Rap1 activator (Fig. 7). Hence, first homophilic VE-cadherin 
contacts may autonomously enhance adherens junction assembly. Both the cAMP-Epac-Rap1 
and the MAGI-I-PDZ-GEF1-Rap1 pathways may interfere with VE-cadherin-based junctions 
by controlling the cortical actin cytoskeleton. 
Although the regulation mechanisms linking AJ and the cytoskeleton are probably not 
fully elucidated, it is possible to conclude that the VE-cadherin complex is an actor of 
vascular morphogenesis through actin remodeling, as well as an integrator of endothelial 
stimuli and physiological state. 
 
 
THE ENDOTHELIAL TIGHT JUNCTION 
 
TJs show considerable variability among different segments of the vascular tree [2]. This 
disparity constitutes a major evidence of vascular bed differentiation of endothelial cells and 
has a strong impact on vascular permeability and leukocyte extravasation. Variations concern 
the complexity degree of the occluding strands as well as TJ composition. 
Large artery endothelial cells, which are exposed to high flow rates, display a well-
developed system of TJ. Within the microvasculature, TJ are less complex in capillaries than 
in arterioles, and even less in venules. As previously mentioned, post-capillary venules are the 
primary site of leukocyte extravasation, and accordingly, they display a high content of 
permeability mediator receptors, such as those for histamine, serotonin and bradykinin. At the 
opposite, the blood brain barrier (BBB) and the blood retinal barrier (BRB) are particularly 
rich in TJ and endothelial TJs have been mostly studied in these locations (as reviews, see [2, 
28, 131-135]). It is currently admitted that the BBB/BRB TJ phenotype is induced by 2 
perivascular cell types: the astrocytes through their cellular processes (end foot) and the 
closely associated pericytes. Both cells produce factors, including angiopoietin-1, TGF and 
probably other uncharacterized molecules, that are required to induce the barrier phenotype 
and [136-138].  
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As discussed below, some of TJ components are specific to endothelial cells. In addition, 
the same molecules might be differentially assembled and regulated in endothelial versus 
epithelial TJs. As previously mentioned, we will concentrate herein on TJ molecules and 
mechanisms specific to endothelial cells. The general organization of TJs is described in 
chapters 2-3 and in previous reviews [28, 139]. It should be noted that information regarding 
TJ component properties mostly derives from studies on epithelial cells because of lack of 
convenient endothelial cell models retaining TJ. 
 
Claudins, occludin and the submembrane TJ complex 
Claudin family members are the major TJ transmembrane constituents, exhibiting 
homophilic and heterophilic (with other claudin subtypes) adhesive activities through their 
extracellular domains and forming the TJ strands [135]. As previously mentioned, endothelial 
TJs specifically and highly express claudin-5, with a few exceptions [140]. Claudin-5-
deficient mice have selective impairment in BBB function for molecules smaller than 800 Da 
[141]. This phenotype suggests a partial redundancy between claudin subtypes. Yet, claudin-3 
and -11 have also been characterized in endothelial cells [142-145]. Initial identification of 
claudin-1 and -12 [141, 146] in the endothelium is now largely questioned and was not 
confirmed. Beside their barrier function, claudins also behave as specific channels and their 
diversity reflects their differential function in paracellular transport [147]. A number of 
pathological settings associated with decreased BBB function were correlated with lower 
claudin expression, thereby indicating that claudins may be therapeutic targets in brain edema 
lesions [144, 146, 148-152]. 
Another transmembrane component of TJ strands is occludin. Although not necessary for 
TJ strand formation, occludin is associated with increased TJ barrier function. In the 
endothelium, this molecule is specifically expressed in the BBB and the BRB [12] and its 
expression is increased with pericyte-derived angiopoietin-1 [136]. Whereas occludin 
downregulation has been observed in various disease state associated with BBB or BRB 
disruption, including stroke, diabetes as well as hypoxia/aglycemia [153-158]. Nevertheless, 
the fact that genetic ablation of occludin does not affect endothelial TJ organization or 
permeability is intriguing and may indicate differential functions in man and mouse [159].  
Decreased occludin contents together with increased paracellular permeability were 
observed in VEGF-treated retinal endothelial cells by a proteolytic mechanism depending on 
urokinase plasminogen activator (Fig. 8) [153, 160]. Occludin proteolysis by 
metalloproteinases was also observed after protein tyrosine phosphatase inhibition or 
monocyte diapedesis [161, 162]. These features suggest that occludin degradation may be one 
of the mechanisms increasing vascular permeability. VEGF activation also leads to occludin 
phosphorylation on serine/threonine residues through PKC activation in correlation with 
increased permeability (Fig. 8) [163, 164]. Upon VEGF treatment, occludin is phosphorylated 
on multiple serine and threonine residues, however the identification of the precise 
phosphorylation sites and their molecular function remain elusive [154]. Other factors, 
namely lysophosphatidic acid, histamine, oxidized phospholipids, monocyte chemoattractant 
protein-1 (MCP-1 or CCL-2) or shear-stress, induce both occludin phosphorylation on 
serine/threonine residues and increased permeability (Fig. 8) [165-168]. But paradoxically, 
angiotensin-2 was shown to increase blood brain barrier function in correlation with increased 
threonine phosphorylation of occludin together with its mobilization to lipid rafts (Fig. 8) 
[169]. Thus, the functional consequences of occludin phosphorylation may be phospho-site-
dependent. Stamatovic et al. [168] demonstrated that MCP-1, in addition to occludin, also 
targets ZO-1, ZO-2 (see below) and claudin-5 phosphorylation on serine/threonine residues 
by a signaling pathway involving Rho and PKC. Occludin may also be phosphorylated on 
tyrosine residues following cerebral ischemia and angiotensin-2 has a negative impact on 
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occludin tyrosine phosphorylation level (Fig. 8) [168, 170]. In conclusion, inflammatory or 
angiogenic mediators alter BBB function in part by acting on occludin integrity, localization 
or phosphorylation level. Conversely, hydrocortisone treatment, through its anti-inflammatory 
properties, increased occludin levels and barrier properties of retinal endothelial cells [171].  
Claudins and occludin are linked to numerous intracellular partners, including ZO-1, -2 
and -3, AF-6/afadin, PAR-3, cingulin and 7H6 antigen, also present in epithelial TJs [28]. 
These proteins form a molecular complex at the submembrane side of TJs. Detailed properties 
of these proteins and their molecular interactions are reviewed in other chapters and reviews 
[149]. Interestingly, two versions of ZO-1 resulting from alternative splicing may be found. 
An 80 amino-acid domain, called , may be inserted in the central part of the protein. 
Whereas the ZO-1+ variant is found in most epithelial cells, the ZO-1- isoform is only 
observed in endothelial cells, Sertoli cells and podocytes of kidney glomeruli [172-174]. In 
general, the ZO-1- isoform characterizes more dynamic junctions. Symplekin, another 
protein located in the TJ complex of some epithelia, is absent in endothelial cells [175].  
 
The JAMs 
JAM-A, -B, and -C constitute a family of transmembrane adhesive proteins belonging to 
Ig superfamily that colocalize with TJ, although not included in TJ strands [20]. Of note, 
JAM-B localization at TJ has been challenged [176]. JAM-A is located in epithelial and 
endothelial intercellular junctions and at the surface of platelets and leukocytes [13, 177], 
while JAM-C expression is restricted to endothelial cells of lymphatic sinuses and high 
endothelial venules of lymphatic organs, as well as smooth muscle cells, fibroblasts and some 
blood cells; however its tissue distribution varies between mouse and human (see [178] and 
references therein and [179]). JAM-B is expressed at interendothelial junctions [180] but its 
tissue distribution is less documented than the two other members.  
JAM-A develops homophilic adhesive activity, suggesting that it may mediate 
endothelial cell-cell interaction. Its barrier function is further demonstrated by use of blocking 
antibodies or peptides [181, 182]. Furthermore, the presence of JAM-A at intercellular 
junctions reduces paracellular permeability [13]. Intracellularly, it interacts with several 
members of TJ complex (see [183], for more details), as well as the PAR-3/aPKC/PAR-6 
polarity complex, suggesting that JAM-A may be involved in the establishment of apical-
basal polarity. Most recent studies on JAM-A are focused on its role in leukocyte 
transmigration. In inflammatory conditions, JAM-A is redistributed at the apical surface [184, 
185]. JAM-A, together with PECAM, CD99 [20] and other JAMs (see below), facilitates 
leukocyte transmigration through the intercellular cleft. During diapedesis, JAM-A binds 
heterophilically to Lß2 integrin located on leukocytes [186]. The phenotype of JAM-A-
deficient mice confirmed its activity in neutrophil transmigration and unveiled other functions 
including the restriction of dendritic cell trafficking in lymph nodes or its participation in 
bFGF-induced angiogenesis [187-190].  
JAM-C develops homophilic binding at interendothelial junctions, where it may also 
interact, even with higher affinity, with JAM-B [191, 192]. As opposed to JAM-A, junctional 
localization of JAM-C increases paracellular permeability, possibly by modulating VE-
cadherin cell-cell contacts [176, 193]. JAM-C promotes neutrophil transmigration via its 
binding to the leukocyte integrin Mß2 [192], but this activity is lost under shear-stress 
conditions, suggesting a weak interaction [194]. Two reports indicate that tumor cells also 
express JAM-C at their surface [195, 196]; this feature may promote the metastatic potential 
of these cells by facilitating their adhesion to endothelial cells via homophilic binding and 
their subsequent transmigration. JAM-C also regulates tumor cell migration by regulating 
integrin activity [197]. JAM-C-deficient mice exhibit growth retardation and pneumonia 
causing poor survival of the mice [198]. Additionally, the number of circulating granulocytes 
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is increased, which seems to be caused by loss of endothelial JAM-C as its rescue in 
endothelial cells is sufficient to restore homeostasis and better survival.  
ESAM is a transmembrane Ig protein related to JAMs [18]. Its expression is restricted to 
endothelial cell TJs and to the surface of activated platelets. ESAM mediates homophilic 
binding and its only known cytoplasmic binding partner is MAGI-I [199]. ESAM-deficient 
mice showed defective tumor angiogenesis, whereas physiological angiogenesis was normal 
[200]. Endothelial ESAM also participates in neutrophil extravasation by a mechanism 
involving Rho activation and TJ destabilization [201].  
Collectively, these data indicate that JAM/ESAM family members have pivotal and 
selective functions in leukocyte trafficking and may also influence TJ dynamics. 
 
Nectins 
Nectins form another group of cell-cell adhesion molecules belonging to the Ig 
superfamily [15, 202, 203]. Four members have been described, nectin 1-4, as well as five 
nectin-like molecules, Necl 1-5. Nectin C-terminus interacts with the PDZ domain of 
afadin/AF-6, an actin filament-binding protein, which connects them to the actin cytoskeleton 
(Fig. 4). Nectin/afadin were found associated with TJ and AJ proteins. They participate in the 
initial step of junction formation and play a fundamental role in the establishment of polarity. 
The nectin-like molecules do not exhibit a PDZ-binding motif and do not interact with afadin.  
So far, only nectin-2 and Necl-5 were identified in endothelial cells [14, 204]. Nectin-2 is 
an -herpes receptor and Necl-5 is the poliovirus receptor [202] and thus both receptors may 
be involved in viral dissemination. Nectin-2 develop homophilic as well as heterophilic 
interactions with nectin-3, while Necl-5 does not develop homophilic binding but interacts 
with nectin-3 [15]. Necl-5 is a potential receptor for DNAM-1/CD226, a transmembrane 
glycoprotein expressed on a subset of B cells and all T cells, natural killer cells, monocytes 
and platelets. Necl-5 facilitates monocyte transmigration through endothelial monolayers and 
may thus participates in inflammatory processes in vivo. Nectin-2, which is also a DNAM-1 
ligand in other cell types, does not seem to play a similar role in endothelial cells [14].  
 
FUTURE DIRECTIONS 
In the recent years, the number of adhesive proteins at interendothelial junctions has 
stabilized and their contribution to barrier function has been relatively well established. 
Nevertheless, a comprehensive view of the proteins located on the cytoplasmic side of AJ and 
TJ is still missing. For example, after years of investigation, the molecular link between the 
actin cytoskeleton and the AJ remains elusive. The molecular network in both junction types 
is probably more complex and variable according to location and pathophysiological state 
than hitherto thought. A number of endothelial adhesive proteins are implicated in leukocyte 
adhesion and transmigration; their specific and sequential actions in these processes remain to 
be clarified. Finally, some of these proteins have demonstrated function in angiogenesis or 
cell migration through mechanisms that need to be fully investigated. 
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FIGURE LEGENDS 
 
Fig. 1: Electron micrograph showing an endothelial junction in mouse aorta 
The intercellular cleft (between arrowheads) is lined by two endothelial (E) strands and 
extands from basal lamina to lumen (L).  
 
Fig. 2: Adhesive proteins within the interendothelial cleft 
Claudins, occluding, JAMs and ESAM are located in TJs, VE-cadherin in Ajs and connexins 
in gap junctions. Nectin was detected in both Ajs and TJs, while PECAM, Pcdh12, CD99 and 
S-endo-1 are outside of these structures. TJs and Ajs are both linked to the actin cytoskeleton 
and VE-cadherin may also be associated with vimentin filaments in some vascular beds.  
 
Fig. 3: Model of hexameric assembly of VE-cadherin extracellular domains deduced 
from biochemical analyses and electron-microscopy 
Model includes VE-cadherin ectodomains (EC) 1-4. Left: model with the VE-cadherin dimers 
represented in violet, light-green and light-blue. Right: The fit of the VE-cadherin model in 
the reconstructed hexamer. EC1 (red), EC2 (green), EC3 (cyan) and EC4 (blue) are coloured 
as indicated. Reproduced from [27] 
 
Fig. 4: Adherens junctions and complexus adherentes in endothelial cells 
In AJs, VE-cadherin directly interacts at a membrane-distal site with - and ß-catenins and at 
a juxtramembrane site with p120 and p0071. The exact molecular link between the VE-
cadherin-catenin complex and the actin filaments is still obscure. The nectins are linked to the 
actin cytoskeleton via afadin. In complexus adherens, VE-cadherin associates with vimentin 
filaments via plakoglobin/desmoplakin or p0071.  
 
Fig. 5: VEGF-induced VE-cadherin phosphorylation and internalization via Src kinase  
A. VEGF activation induces VEGFR2 dimerization, enabling Src activation, which in turn 
phosphorylates VE-cadherin on Tyr-685 [71, 73]. Csk may associate with VE-cadherin 
phospho-tyr-685. This interaction was shown to inhibit proliferation in high density cell 
cultures [74]. Csk-VE-cadherin interaction may potentially inhibit VE-cadherin-associated 
Src by phophorylating an inhibitory tyrosine in Src C-terminus domain. 
B. Independently,VEGF was shown to induce an activation cascade (Src  Vav2  Rac  
PAK kinase) leading to phosphorylation of VE-cadherin cytoplasmic domain on serine 665. 
Phospho-S665 VE-cadherin becomes a docking site for ß-arrestin-2, the binding of which 
triggers VE-cadherin endocytosis and degradation, and thus, junction opening [76]. More 
work is necessary to examine the interplay between both pathways. 
 
Fig. 6: Participation of VE-cadherin to VEGF signaling 
It is clearly established that VE-cadherin has a pivotal role in contact inhibition of cell 
proliferation. VE-cadherin, through its interaction with Dep-1 or other tyrosine phosphatases 
inhibits VEGF proliferation signal via MAPK activation in three ways: (i) by reducing 
VEGFR2 phosphorylation, (ii) by inhibiting VEGFR2-associated Shc phosphorylation and 
(iii) by decreasing VEGFR2 internalization and signaling from endosomal compartments. 
VE-cadherin complex interaction with activated VEGFR2 also enhances VEGF survival 
signaling by PI3kinase/Akt pathway. 
 
Fig. 7: Rap1 activation pathways and stabilization of the endothelial barrier 
Increased levels of intracellular cAMP by G-protein-coupled receptors enable the activation 
of the exchange factor Epac, which is a specific activator of Rap1, a Ras family GTPase. 
28 
Rap1 activation promotes AJ extension by increasing the avidity of cortical actin to the VE-
cadherin complex. Rap1 may also be activated by the adaptator protein MAGI-I together with 
the exchange factor PDZ-GEF1, recruited at the VE-cadherin complex. These data are derived 
from [128-130]. 
 
Fig. 8: Cytokines activating signaling pathways leading to occludin functional 
alterations (phosphorylation or proteolysis) 
VEGF, MCP-1, lysophosphatidic acid (LPA) and histamine (Hist), by interaction with their 
cognate receptors, VEGFR2, CCR2, LPAR and HistR, respectively, induce increased 
occludin phosphorylation on serine/threonine residues, in correlation with increased 
permeability. Signaling pathways involve PKC activity, PKC and/or RhoA, as indicated 
[163, 164, 167, 168]. VEGF also increases permeability by inducing occludin proteolysis 
through activation of the urokinase (uPA)/uPAR system [153, 160]. Conversely, angiotensin-
2 (AT2) binding to type 1 angiotensin receptor (ATR) decreases permeability by inducing 
threonine phosphorylation and tyrosine dephosphorylation of occludin [169]. 
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